Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.

Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol. 2002 Jun; 117(4):886-9.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.